TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2893865
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin (6 million units/day for 7 days)
Study: 31749238
Drug: Bexagliflozin 5
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin 5 mg
Study: 31749238
Drug: Bexagliflozin 10
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin 10 mg
Study: 31749238
Drug: Bexagliflozin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin (all doses)
Study: 31381171
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alcohol (mean BrAC = 0.11%)
Study: 31381171
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of alcohol (mean BrAC = 0.04%)
Study: 28969667
Drug: CRP point-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP point-of-care test (POCT) to guide antibiotic prescribing
Study: 14982685
Drug: bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion (300 mg) with behavioral counseling for 10 weeks
Study: 21431408
Drug: CRS +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRS + HIPEC (cisplatin 120 mg and mitomycin C 30 mg in 6000 ml of normal saline at 43 ± 0.5°C for 60-90 min)
Study: 18305083
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 32 ml kg(‐1) (NS32)
Study: 10606834
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fosinopril (n=12 patients)
Study: 10606834
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg enalapril (n=12 patients)
Study: 10606834
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fosinopril (n=16 patients)
Study: 10606834
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg lisinopril (n=15 patients)
Study: 8240458
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg/day for 3 weeks
Study: 25282563
Drug: Daily emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily emollient therapy applied at least once per day starting within 3 weeks of birth
Study: 21073605
Drug: OAB-M-F (metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAB-M-F (metronidazole 500 mg bid for 5 days, followed by furazolidone 200 mg bid for 5 days)
Study: 21073605
Drug: OAC-P (clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC-P (clarithromycin 500 mg bid for 10 days, placebo)
Study: 21073605
Drug: OAB-C-F (clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAB-C-F (clarithromycin 500 mg bid for 5 days, followed by furazolidone 200 mg bid for 5 days)
Study: 17713873
Drug: 2% sage
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sage extract (SE) in a hydrophilic ointment
Study: 12153334
Drug: Nefazodone (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (starting at 50 mg/day, increasing to 200 mg/day, and up to 600 mg/day if tolerated)
Study: 2521552
Drug: Inhaled pirenzepine
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled pirenzepine (70 micrograms)
Study: 28505360
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefazolin (500 mg h-1)
Study: 28505360
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus of cefazolin (2 g every 4 h)
Study: 25005464
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 gram orally 3 times daily for 3 months)
Study: 25005464
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 gram orally 3 times daily for 3 months)
Study: 23958263
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 6 months
Study: 16983692
Drug: Particulate water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particulate water (via aerosol spray)
Study: 16357661
Drug: Developmental physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmental physical therapy (PT) from birth until four months corrected age (CA), weekdays during the neonatal stay and on a needs- and problem-oriented basis thereafter.
Study: 10500946
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg kg‐1 (Group M)
Study: 6859607
Drug: Thiopental 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 3 mg/kg, iv, followed by inhalation of 100% oxygen and a continuous intravenous infusion of thiopental 0.2‐0.3 mg X kg‐1 X min‐1
Study: 6859607
Drug: Thiopental 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 3 mg/kg followed by inhalation of halothane (1.5% end‐tidal concentration) in oxygen
Study: 6859607
Drug: Thiopental 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 3 mg/kg followed by inhalation of 70% nitrous oxide in oxygen
Study: 31409425
Drug: Postoperative guideline
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative guideline rehabilitation plus Classic follow-up treatment
Study: 27142743
Drug: Theaflavins (TF)
Normalized name: theaflavin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theaflavins (TF) 10mg/kg single oral dose
Study: 22315746
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) nasal spray 110 microg/day
Study: 22315746
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) nasal spray 200 microg/day
Study: 17928806
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg elemental calcium daily for 30 days (n=24)
Study: 16905024
Drug: Mass antibiotic
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass antibiotic treatment (azithromycin)
Study: 10233493
Drug: VIP/P-1 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP/P-1 (25 micrograms VIP combined with 1.0 mg PM)
Study: 10233493
Drug: VIP/P-2 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP/P-2 (25 micrograms VIP combined with 2.0 mg PM)
Study: 353721
Drug: Nomifensine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine, 4 capsules daily for 4 weeks
Study: 353721
Drug: Nortriptyline, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline, 4 capsules daily for 4 weeks
Study: 31278694
Drug: Morphine ARER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine ARER 100 mg under fed conditions
Study: 31278694
Drug: Morphine ARER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine ARER 100 mg under fasted conditions
Study: 28557548
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) at 20-60 mg/day
Study: 28557548
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT)
Study: 26559364
Drug: Wet-cupping (hijama)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet-cupping (hijama) in addition to conventional hypertension treatment
Study: 26559364
Drug: Conventional hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hypertension treatment only
Study: 16927385
Drug: Short and
Normalized name: ALLERGENIC EXTRACT,RAGWEED,SHORT AND TALL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short and long term family therapy
Study: 9499549
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg medrogeston for six cycles
Study: 9499549
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dydrogesteron for six cycles
Study: 2677376
Drug: Trimazosin (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin (50‐200 mg twice daily)
Study: 2677376
Drug: Propranolol (40‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40‐160 mg twice daily)
Study: 1108350
Drug: Trimethoprim-sulphamethoxazole, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulphamethoxazole, 2 tablets twice a day
Study: 1108350
Drug: Ampicillin, 500
Normalized name: Ampicillin, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 500 mg four times a day
Study: 26094857
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor blockade by exendin-9-39
Study: 19632976
Drug: Quit Smoking
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quit Smoking Network (QSN) treatment program
Study: 19632976
Drug: Non-assigned treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-assigned treatments (various types)
Study: 9409050
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg tablets, two tablets administered pre-operatively)
Study: 9409050
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two matching placebo tablets administered pre-operatively)
Study: 8287650
Drug: 5-hydroxy-L-tryptophan
Normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxy-L-tryptophan
Study: 8287650
Drug: gamma-L-glutamyl-5-hydroxy-L-tryptophan
Normalized name: L-glutamyl-L-tryptophan
DrugBank: Oglufanide (DB05779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-L-glutamyl-5-hydroxy-L-tryptophan
Study: 3518771
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release nifedipine 40 mg at 1 and 12 h
Study: 3518771
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg at 0 h
Study: 20519807
Drug: Miglitol administered
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol administered at 30 min after the start of a meal (50 mg)
Study: 12907008
Drug: MnCC control
Approvals — FDA: no, EMA: no, PMDA: no
Description: MnCC control vaccine
Study: 8737229
Drug: r‐HuEpo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEpo (200 U, subcutaneously administered, three times weekly for 4 weeks)
Study: 7055169
Drug: Laminaria treatment
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria treatment (n = 45)
Study: 30783732
Drug: Mometasone (inhaled)
Normalized name: mometasone Inhalant Product
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone (inhaled)
Study: 17580534
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once daily (n = 18)
Study: 17580534
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin twice daily (n = 15)
Study: 17580534
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin once daily at bedtime with more intensive self-monitoring (n = 15)
Study: 9672774
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg o.d. for 10 days)
Study: 30783776
Drug: Collagen peptides
Normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen peptides (CP) 20 g day−1
Study: 26867337
Drug: Thymosin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin therapy (1.6 mg subcutaneous injection, qd X 7 d)
Study: 26867337
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (ICU conventional treatment)
Study: 22763798
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (7 g/day for 1 week)
Study: 21971663
Drug: L‐Ala‐Gln 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐Ala‐Gln 20% plus saline 750 ml (Group L‐Ala‐Gln, n=11)
Study: 21971663
Drug: Saline 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 1000 ml (Group Saline, n=11)
Study: 16709595
Drug: No diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diuretic use
Study: 15508179
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with birch pollen extract
Study: 11430776
Drug: Energy restriction
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy restriction (‐2929 kJ/d) and drug therapy (or placebo)
Study: 9153530
Drug: Control (patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (patients prior to treatment)
Study: 7974898
Drug: Colony-stimulating factor
Normalized name: Colony-stimulating factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colony-stimulating factor support for chemotherapy
Study: 7974898
Drug: Adjunctive surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive surgical therapy
Study: 2455188
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine (TC)
Study: 2455188
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (OP)
Study: 25720615
Drug: Lactobacillus brevis
Normalized name: Lactobacillus brevis
DrugBank: Lactobacillus brevis (DB18532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus brevis CD2 lozenges, three times daily for 14 days
Study: 25720615
Drug: Placebo, three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, three times daily for 14 days
Study: 10811265
Drug: Calcium pentosan
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium pentosan polysulphate (CaPPS) 10 mg/kg orally, once weekly for four weeks, repeated every 12 weeks.
Study: 8781669
Drug: L-ASA (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ASA (90 mg/ml)
Study: 8781669
Drug: Placebo (glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glycine solution 30 mg/ml)
Study: 1616392
Drug: Mefloquine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 15 mg kg-1 (M15)
Study: 1616392
Drug: Mefloquine 25
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 25 mg kg-1 (M25)
Study: 1616392
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) treatment failures treated with Mefloquine 25 mg kg-1
Study: 25304187
Drug: Antenatal distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal distribution of misoprostol (for self-administration after home birth or when oxytocin is not available)
Study: 8551485
Drug: Verapamil 120-240
Normalized name: verapamil hydrochloride 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120-240 mg once daily for 8 weeks
Study: 7008821
Drug: Azatadine maleate
Normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azatadine maleate (4 mg/day for 1 week)
Study: 22002564
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy concurrent with letrozole 2.5 mg (study arm, n = 50)
Study: 22002564
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy alone (control arm, n = 51)
Study: 19307972
Drug: Propofol target-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-controlled infusion based on a weight adjustment formula (group adjusted)
Study: 19307972
Drug: Propofol target-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-controlled infusion without adjustment (group total body weight - TBW)
Study: 14993502
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (1.5-2.0 mg/kg/day for 12 months) and steroids (methylprednisolone pulses 3 x 1 g, i.v. at months 1, 3 and 5, and oral prednisone 0.5 mg/kg/48 h for 6 months)
Study: 14993502
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (not specified treatment)
Study: 2239778
Drug: Vegetable-protein mixed
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable-protein mixed diet at 96, 128, 160, and 192 mg N.kg body wt‐1.d‐1 for 10 days
Study: 2239778
Drug: Milk-egg protein
Normalized name: milk protein concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-egg protein diet at 160 mg N.kg‐1.d‐1 for 10 days
Study: 348260
Drug: Metoprolol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 300 mg in a single daily dose
Study: 348260
Drug: Metoprolol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 300 mg/day in three doses
Study: 27941119
Drug: Oral amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin, 2 times daily for 7 days
Study: 27941119
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 times daily for 7 days
Study: 24828121
Drug: Drinking 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking 400 mL water
Study: 24828121
Drug: Drinking 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking 400 mL water and eating a 6-inch Subway sandwich
Study: 24828121
Drug: Drinking 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking 400 mL water and composing 3 text messages
Study: 23421352
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU intranasal oxytocin for 10 consecutive days
Study: 19169446
Drug: 0.2% solution
Normalized name: Naropin 0.2% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% solution of CHX
Study: 19169446
Drug: 0.12% solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% solution of CHX
Study: 19169446
Drug: 0.2% gel
Normalized name: SIROLIMUS 0.2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% gel
Study: 19169446
Drug: 0.2% spray
Normalized name: HYALURONATE NA 0.2% SPRAY,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% spray
Study: 19169446
Drug: 0.12% spray
Normalized name: BENZETHONIUM CL 0.12% SPRAY,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% spray
Study: 19169446
Drug: swab with
Normalized name: Suction Swab with Corinz Oral Rinse KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: swab with 0.2% solution
Study: 15781531
Drug: Heparinized flush
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized flush solution (group H, n = 100)
Study: 15781531
Drug: Nonheparinized flush
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonheparinized flush solution (group S, n = 100)
Study: 15781531
Drug: Heparinized flush
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized flush solution (group H)
Study: 15781531
Drug: Nonheparinized flush
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonheparinized flush solution (group S)
Study: 8742916
Drug: Vasopressin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (0.3 U/min) plus nasal oxygen (4 L/min)
Study: 1655647
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (50 ng x kg-1 x min-1)
Study: 25192333
Drug: NP001 (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP001 (0.2, 0.8, 1.6, and 3.2 mg/kg, single i.v. dose)
Study: 20848453
Drug: NI-0401 (0.05-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NI-0401 (0.05-10 mg daily for 5 days)
Study: 20848453
Drug: NI-0401 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NI-0401 (1 mg)
Study: 17428106
Drug: Montelukast with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast with antihistamines (loratadine or cetirizine)
Study: 9857783
Drug: Medication noncompliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication noncompliance and substance abuse
Study: 9857783
Drug: Problems with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problems with both alcohol and illicit drug abuse
Study: 9857783
Drug: Improving medication
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Improving medication adherence in the context of integrated mental health and substance abuse treatment
Study: 7542829
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean daily dose 8 mg)
Study: 7542829
Drug: Zuclopenthixol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuclopenthixol (mean daily dose 38 mg)
Study: 31564184
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy with 20 Gy in five fractions followed by four cycles of chemotherapy (FOLFOX regimen)
Study: 29723460
Drug: Qilan Capsules
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qilan Capsules + androgen‐deprivation therapy
Study: 29723460
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + androgen‐deprivation therapy
Study: 22472905
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PT and RM
Study: 26490089
Drug: benidipine-β-blocker
Normalized name: barnidipine
DrugBank: Barnidipine (DB09227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine-β-blocker